All In Biotech

Drug Trial Radar · NCT06118255

A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Fenfluramine (Hydrochloride) in Infants 1 Year to Less Than 2 Years of Age With Dravet Syndrome

Open-Label, Single-Arm, Phase 3 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Fenfluramine (Hydrochloride) in Infants 1 Year to Less Than 2 Years of Age With Dravet Syndrome

Last checked: Nov 20, 2026Latest source record: Sep 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

25

Actual

Start

May 21, 2024

Primary completion

Sep 1, 2026

Study completion Sep 1, 2026

Sponsor

Lead sponsor
UCB BIOSCIENCES, Inc.UCB
Sponsor type
Industry
First posted
Nov 7, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 1 year, up to 23 months
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of this study is evaluate the safety and tolerability of fenfluramine hydrochloride (HCl) 0.2 to 0.8 mg/kg/day in infants 1 year to less than 2 years of age with Dravet syndrome.

Conditions

  • Dravet Syndrome

Interventions

  • fenfluramineDrug

    The study drug, fenfluramine HCl, is an oral solution to be administered in equal doses twice daily (BID). It will be based on the current dose and participant's weight (kg).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from Baseline in QT interval corrected by Fridericia (QTcF) at Visit 13 (End of Treatment/Early Termination (EOT/ET))Time frame: Week 52 (Visit 13; EOT/ET), compared to Baseline
  2. Occurrence of a treatment-emergent (ie, post-Baseline through Visit 13 [EOT/ET]) result which meets the FDA case definition of drug associated valvulopathyTime frame: From post-Baseline (Day 1) through Visit 13 (EOT/ET) (up to 52 weeks)
  3. Occurrence of treatment-emergent (ie, post-Baseline through Visit 13 [EOT/ET]) clinically confirmed valvular heart disease (VHD)Time frame: From post-Baseline (Day 1) through Visit 13 (EOT/ET) (up to 52 weeks)
  4. Change from Baseline in body weight (Z-score) at each visitTime frame: Week 1 (Visit 3), Week 4 (Visit 5), Week 8 (Visit 7), Week 12 (Visit 8), Week 16 (Visit 9), Week 20 (Visit 10), Week 26 (Visit 11), Week 39 (Visit 12), Week 52 (Visit 13), Postdose Safety Follow-Up (Visit 14), compared to Baseline
  5. Change from Baseline in recumbent length (Z-score) at each visitTime frame: Week 1 (Visit 3), Week 4 (Visit 5), Week 8 (Visit 7), Week 12 (Visit 8), Week 16 (Visit 9), Week 20 (Visit 10), Week 26 (Visit 11), Week 39 (Visit 12), Week 52 (Visit 13), Postdose Safety Follow-Up (Visit 14), compared to Baseline
  6. Occurrence of a clinically significant abnormality on the neurological examination at each visitTime frame: Week 1 (Visit 3), Week 4 (Visit 5), Week 8 (Visit 7), Week 12 (Visit 8), Week 16 (Visit 9), Week 20 (Visit 10), Week 26 (Visit 11), Week 39 (Visit 12), Week 52 (Visit 13), Postdose Safety Follow-Up (Visit 14), compared to Baseline

Locations

12 sites in 5 countries. Site status is shown where the registry gives one.

  • Ep0213 105

    Memphis, Tennessee

  • Ep0213 107

    Dallas, Texas

  • Ep0213 103

    Seattle, Washington

  • Ep0213 502

    Brussels, Belgium

  • Ep0213 501

    Edegem, Belgium

  • Ep0213 303

    Bielefeld, Germany

  • Ep0213 202

    Florence, Italy

  • Ep0213 203

    Genova, Italy

  • Ep0213 201

    Roma, Italy

  • Ep0213 204

    Roma, Italy

  • Ep0213 403

    Glasgow, United Kingdom

  • Ep0213 401

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.